1
项与 Anti-TnMUC-1 CAR-T cell therapy (Tmunity Therapeutics) 相关的临床试验A Phase 1 Open-Label, Multi-Center First in Human Study of TnMUC1-Targeted Genetically-Modified Chimeric Antigen Receptor T Cells in Patients With Advanced TnMUC1-Positive Solid Tumors and Multiple Myeloma
Multi-center, open-label, first in human Phase 1 study of the safety, tolerability, feasibility, and preliminary efficacy of the administration of genetically modified autologous T cells (CART-TnMUC1 cells) engineered to express a chimeric antigen receptor (CAR) capable of recognizing the tumor antigen, TnMUC1 and activating the T cell (CART- TnMUC1 cells).
100 项与 Anti-TnMUC-1 CAR-T cell therapy (Tmunity Therapeutics) 相关的临床结果
100 项与 Anti-TnMUC-1 CAR-T cell therapy (Tmunity Therapeutics) 相关的转化医学
100 项与 Anti-TnMUC-1 CAR-T cell therapy (Tmunity Therapeutics) 相关的专利(医药)
100 项与 Anti-TnMUC-1 CAR-T cell therapy (Tmunity Therapeutics) 相关的药物交易